Researchers compared Epi proColon to computed tomographic colonography, PillCam and Cologuard. Researchers compared clinical effectiveness through five different scenarios, including a scenario that assumed the Epi proColon missed 12 percent of advanced adenomas and 18 percent of CRC cases.
What they found:
1. Annual screening with Epi proColon had an incremental cost-effectiveness ratio of $63,253 for every quality-adjusted life year gained.
2. CTC every five years had a ratio of $1,092 and annual Cologuard screening had a ratio of $214,974.
3. Researchers used a “willingness-to-pay” threshold of $100,000 for quality-adjusted life years gained.
4. Epi proColon was more cost-effective than Cologuard in all scenarios, but the authors concluded that the best test was the “one that gets done.”
More articles on physicians:
What CMS’ proposal to eliminate the inpatient only list means for ASCs
21 surgery center developments costing $10M+
‘We want people to understand why we’re upset’ — 5 surgery, specialty group leaders on CMS’ proposed 2021 fee schedule
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
